Home | News | Directories | Calendar | Maps | Contact Us | Webmail
Perelman School of Medicine at the University of Pennsylvania Advanced Search

Susan R. Rheingold, MD

Susan R. Rheingold, MD

faculty photo
Associate Professor of Clinical Pediatrics
Department: Pediatrics

Contact information
Children's Hospital of Philadelphia
Colket Translational Research Building
Room 10052, Oncology
Philadelphia, PA 19104
Philadelphia, PA 19104
Office: 215 590-3079
Fax: 215-590-4183
Dartmouth College (magna cum laude), 1988.
University of Pennsylvania School of Medicine, 1992.
Permanent link
Perelman School of Medicine > Faculty > Search

Description of Research Expertise

Since my appointment as Associate Professor, I have continued to expand the clinical trial as to children with relapsed hematologic malignancies, with a focus on childhood and adolescent ALL. These programs include clinical trials for newly diagnosed ALL, supportive care during ALL therapy, and experimental therapeutics for relapsed ALL. I am the institutional principal investigator (PI) for the majority of Children’s Oncology Group (COG), industry, and institutional ALL protocols available at CHOP. I am an active member of the COG Relapsed ALL Committee and am a member of the national study committees for the COG relapsed ALL trials ADVL04P2, AALL0433, and AALL07P1.

I am in my second year of a three year Leukemia Lymphoma Society Translational Research Grant introducing mTOR inhibitors into pediatric clinical trials. A protocol combining temsirolimus with intensive chemotherapy for relapsed ALL and Non-Hodgkin’s Lymphoma (NHL) will be run through the Children’s Oncology Group as a combined protocol between the developmental therapeutics, ALL, and NHL committees, with myself as the National PI. The Leukemia & Lymphoma Society Grant has also let me expand upon an institutional Phase I trial of sirolimus, an oral mTOR inhibitor. Based upon the preclinical work of my co-investigators, Stephen Grupp, MD, PhD and David Teachey, MD, which showed maintenance of complete remission of NOD/SCID mice with ALL using sirolimus and methotrexate, I am PI on an institutional Phase 2 efficacy trial of sirolimus combined with oral methotrexate for children and adolescents with relapsed and refractory ALL and NHL.

The industry sponsored Clofarabine trials, for which I was the local PI, successfully ended with the first new FDA approval for relapsed childhood ALL in over two decades. I have a manuscript in press on a novel combination of chemotherapeutic agents (nelarabine, etoposide, and cyclophosphamide) to treat relapsed T-cell ALL and NHL. Under Eric Kodish, MD (Cleveland Clinic), I am a co-investigator on a R01 funded investigation studying the informed consent process for Phase I pediatric cancer trials.
I also have research interests in oncologic emergencies, supportive care and nutrition/complementary and alternative medicine (CAM) for the pediatric oncology patient, especially as it relates to therapy for children with ALL. In the realm of supportive care and nutrition/CAM for I have collaborated on the following investigations: 1) CAM use in pediatric cancer patients; 2) antioxidant levels and chemotoxicity in ALL patients; 3) milk thistle therapy for hepatotoxicity induced by Maintenance therapy in ALL; 4) erythropoietin use on quality of life; and 5) a pilot study of enteral feeds for high risk pediatric patients. All of these studies have been funded by private foundation grants or industry and several of these studies have now been published. Further grant funding is being sought to run successor trials.

Description of Clinical Expertise

Acute lymphoblastic leukemia (ALL) is the most common type of childhood cancer. Although 80% of children and adolescents are cured with frontline therapy, 20% of patients relapse and have dismal outcomes. I actively participate in both clinical and translational research programs designed to improve outcomes for this population. I am the institutional principal investigator (PI) for the majority of Children’s Oncology Group (COG), industry, and institutional ALL protocols available at the Children’s Hospital of Philadelphia. I am an active member of the COG Relapsed ALL Strategy Group and am a member of the national study committees for several of the COG relapsed ALL trials.

I see the majority of second opinions referred to CHOP for newly diagnosed and relapsed ALL; as well as, communicate by email and phone with outside pediatric oncologists looking for advice on treatment in complex ALL cases. I oversee the care of all of our patients with ALL enrolled on COG trials as well as those not on study being treated with standard of care.

Selected Publications

Johnson L, Leek AC, Drotar D, Noll RB, Rheingold SR, Kodish ED, Baker JN. : Practical communication guidance to improve phase I informed consent conversations and end-of-life decision-making in pediatric oncology. Cancer 121(14): 2439-48, July 2015 Notes: Epub 2015 April 14.

Shannon ML, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, Chew A, Gonzalez VE, Zheng Z, Lacey SF, Mahnke YD, Melenhorst JJ, Rheingold SR, Shen A, Teachey DT, Levine BL, June CH, Porter DL, Grupp SA: Chimeric antigen receptor T cells for sustained remissions in leukemia. New England Journal of Medicine 368(16): 1509-18, April 2014.

Plourde PV, Jeha S, Hijiya N, Keller FG, Silverman LB, Rheingold SR, Dreyer ZE, Dahl GV, Mercedes T, Lai C, Corn T: Safety profile of asparaginase Erwinia chrysanthemi in a large compassionate-use trial. Pediatr Blood Cancer 61(7): 1232-8, July 2014.

Fisher Brian T, Harris Tracey, Torp Kari, Seif Alix E, Shah Ami, Huang Yuan-Shung V, Bailey L Charles, Kersun Leslie S, Reilly Anne F, Rheingold Susan R, Walker Dana, Li Yimei, Aplenc Richard: Establishment of an 11-Year cohort of 8733 pediatric patients hospitalized at United States free-standing Children's hospitals with de novo acute lymphoblastic leukemia from health care administrative data. Medical care 52(1): 1-6, January 2014.

Seif AE, Fisher BT, Li Y, Torp K, Rheam DP, Huang YV, Harris T, Shah A, Hall M, Fieldston E, Vujkovic M, Bailey C, Kersun LS, Reilly AF, Rheingold SR, Walker DS, Aplenc R. : Patient and hospital factors associated with induction mortality in acute lymphoblastic leukemia. Pediatr Blood Cancer 61(5): 846-52, March 2014.

Sacks N, Hwang W-T, Lange BJ, Tan K-S, Sandler ES, Rogers PC, Womer RB, and Rheingold SR: Proactive enteral tube feeding in pediatric patients undergoing chemotherapy. Pediatr Blood Cancer 61(2): 281-5, February 2014.

Maude SL, Fitzgerald JC, Fisher BT, Li Y, Huang Y-S, Torp K, Seif AE, Kavcic M, Walker DM, Leckerman KH, Kilbaugh TJ, Rheingold SR, Sung L, Zaoutis TE, Berg RA, Nadkarni VM, Thomas NJ, Aplenc RA: Outcome of pediatric acute myeloid leukemia patients receiving intensive care in the United States. Pediatr Crit Care Med 15(2): 112-20, February 2014.

Baker Justin N, Leek Angela C, Salas Halle Showalter, Drotar Dennis, Noll Robert, Rheingold Susan R, Kodish Eric D: Suggestions from adolescents, young adults, and parents for improving informed consent in phase 1 pediatric oncology trials. Cancer 119(23): 4154-61, December 2013.

Borst Alexandra J, States Lisa J, Reilly Anne F, Rheingold Susan R: Determining response and recurrence in pediatric B-cell lymphomas of the bone. Pediatr Blood Cancer 60(8): 1281-6, August 2013.

back to top
Last updated: 08/16/2016
The Trustees of the University of Pennsylvania